Loading clinical trials...
Loading clinical trials...
Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance
This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment. Parkinson disease patients with different severity who have already used pramipexole could be observed in this study. In the whole observation period, treatment decision was determined by physician and patient completely. The safety endpoint is AE(Adverse Event), SAE(Serious Adverse Event), patient withdraw, laboratory test.
Purpose:
Age
30 - 75 years
Sex
ALL
Healthy Volunteers
No
Boehringer Ingelheim Investigational Site 54
Beijing, China
Boehringer Ingelheim Investigational Site 55
Beijing, China
Boehringer Ingelheim Investigational Site 56
Beijing, China
Boehringer Ingelheim Investigational Site 57
Beijing, China
Boehringer Ingelheim Investigational Site 58
Beijing, China
Boehringer Ingelheim Investigational Site 59
Beijing, China
Boehringer Ingelheim Investigational Site 60
Beijing, China
Boehringer Ingelheim Investigational Site 61
Beijing, China
Boehringer Ingelheim Investigational Site 62
Beijing, China
Boehringer Ingelheim Investigational Site 63
Beijing, China
Start Date
May 1, 2011
Primary Completion Date
February 1, 2012
Completion Date
February 1, 2012
Last Updated
May 16, 2014
2,017
ACTUAL participants
pramipexole
DRUG
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640